Neuroprotective effect of lurasidone via antagonist activities on histamine in a rat model of cranial nerve involvement

  • Authors:
    • Baoming He
    • Liang Yu
    • Suping Li
    • Fei Xu
    • Lili Yang
    • Shuai Ma
    • Yi Guo
  • View Affiliations

  • Published online on: February 13, 2018     https://doi.org/10.3892/mmr.2018.8595
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Cranial nerve involvement frequently involves neuron damage and often leads to psychiatric disorder caused by multiple inducements. Lurasidone is a novel antipsychotic agent approved for the treatment of cranial nerve involvement and a number of mental health conditions in several countries. In the present study, the neuroprotective effect of lurasidone by antagonist activities on histamine was investigated in a rat model of cranial nerve involvement. The antagonist activities of lurasidone on serotonin 5‑HT7, serotonin 5‑HT2A, serotonin 5‑HT1A and serotonin 5‑HT6 were analyzed, and the preclinical therapeutic effects of lurasidone were examined in a rat model of cranial nerve involvement. The safety, maximum tolerated dose (MTD) and preliminary antitumor activity of lurasidone were also assessed in the cranial nerve involvement model. The therapeutic dose of lurasidone was 0.32 mg once daily, administered continuously in 14‑day cycles. The results of the present study found that the preclinical prescriptions induced positive behavioral responses following treatment with lurasidone. The MTD was identified as a once daily administration of 0.32 mg lurasidone. Long‑term treatment with lurasidone for cranial nerve involvement was shown to improve the therapeutic effects and reduce anxiety in the experimental rats. In addition, treatment with lurasidone did not affect body weight. The expression of the language competence protein, Forkhead‑BOX P2, was increased, and the levels of neuroprotective SxIP motif and microtubule end‑binding protein were increased in the hippocampal cells of rats with cranial nerve involvement treated with lurasidone. Lurasidone therapy reinforced memory capability and decreased anxiety. Taken together, lurasidone treatment appeared to protect against language disturbances associated with negative and cognitive impairment in the rat model of cranial nerve involvement, providing a basis for its use in the clinical treatment of patients with cranial nerve involvement.

Related Articles

Journal Cover

Print ISSN: 1791-2997
Online ISSN:1791-3004

2016 Impact Factor: 1.692
Ranked #19/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
He, B., Yu, L., Li, S., Xu, F., Yang, L., Ma, S., & Guo, Y. (1899). Neuroprotective effect of lurasidone via antagonist activities on histamine in a rat model of cranial nerve involvement. Molecular Medicine Reports, 0, 0-0. https://doi.org/10.3892/mmr.2018.8595
MLA
He, B., Yu, L., Li, S., Xu, F., Yang, L., Ma, S., Guo, Y."Neuroprotective effect of lurasidone via antagonist activities on histamine in a rat model of cranial nerve involvement". Molecular Medicine Reports 0.0 (1899): 0-0.
Chicago
He, B., Yu, L., Li, S., Xu, F., Yang, L., Ma, S., Guo, Y."Neuroprotective effect of lurasidone via antagonist activities on histamine in a rat model of cranial nerve involvement". Molecular Medicine Reports 0, no. 0 (1899): 0-0. https://doi.org/10.3892/mmr.2018.8595